# Pharmacogenomic Study for Providing Personalized Strategy to the Treatment of Non-small Cell Lung Cancer (NSCLC) IIIB/IV

> **NCT01003964** · PHASE2 · COMPLETED · sponsor: **National Cancer Center, Korea** · enrollment: 289 (actual)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** IP
- **DRUG:** GP

## Key facts

- **NCT ID:** NCT01003964
- **Lead sponsor:** National Cancer Center, Korea
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-02
- **Primary completion:** 2015-06
- **Final completion:** 2015-06
- **Target enrollment:** 289 (ACTUAL)
- **Last updated:** 2022-04-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01003964

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01003964, "Pharmacogenomic Study for Providing Personalized Strategy to the Treatment of Non-small Cell Lung Cancer (NSCLC) IIIB/IV". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01003964. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*